We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New MenB Vaccine Has Progressed to Clinical Development

A health care provider placing a plaster on a patients arm after receiving a vaccine.
Credit: CDC / Unsplash.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

In a paper published by Science Translational Medicine, scientists show how they were able to use an existing vaccine delivery platform – similar to the vaccines created to tackle Covid-19 and Ebola – to effectively produce the specific part of the bacteria that triggers the immune system to make protective antibodies.

Professor Christine Rollier, who conducted the research whilst at Oxford University in her role as Associate Professor in Vaccinology at the Oxford Vaccine Group before moving to the University of Surrey said:

"The key challenge in our study was using viral-based vaccine platforms that can successfully generate antibodies against diseases such as rabies and SARS-CoV-2 to work for bacterial infections such as MenB."

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

To meet this challenge, the team used vaccine platforms that expressed a protective protein called "factor H binding protein”. The researchers tested these vectors to see if they could produce the protein reliably and if they could stimulate a strong immune response in mice.

The team identified a promising vaccine candidate, and it was further improved for human use by making small changes to its structures and testing it, once again, on mice with human-like immune systems. The vaccine candidate has progressed to clinical development.

Professor Rollier added:

"While our MenB vaccine has shown strong, consistent, and long-lasting protection against these severe bacteria in mice after a single dose, we understand the complexities of the human immune system. As we progress, we remain cautiously optimistic about its potential to induce similar protective responses in humans.

"More importantly, the application of genetic vaccines such as ours signifies a hopeful leap forward in combating bacterial diseases."

MenB bacteria are a severe cause of life-threatening infections, including meningitis and sepsis. MenB is the predominant group responsible for 90% of meningococcal infections in the UK, according to the NHS. These infections can affect people of all ages but are most common in babies and young children. MenB infections can be fatal, with around 1 in 20 affected children dying from the disease.

Reference: Dold C, Marsay L, Wang N, et al. An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease. Sci Transl Med. 2023;15(701):eade3901. doi: 10.1126/scitranslmed.ade3901

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.